poisar

Crypto · News reference

Bitcoin Tops $80,000, S&P 500 Slips as Yields Reclaim 5%: Stock Market Today

BenzingaPiero Cingari

Crypto-linked equities ripped higher as Bitcoin cleared $80,000, but the S&P 500 slipped with the 10-year Treasury yield back above 5%.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    ASML Rides on Strength in Installed Base Business: Will it Sustain?

    ASML's Installed Base Management sales surged 31.8% year-over-year to €2.8 billion in Q2, exceeding expectations by €300 million. Semiconductor manufacturers are increasingly investing in software-led upgrades to boost productivity without purchasing new equipment. ASML projects over 30% growth in this segment for 2026, driven by expanding EUV installed base and service opportunities.

  2. Zacks Investment ResearchZacks.Com

    The Zacks Analyst Blog Highlights Applied Materials, Philip Morris, Valero Energy, Crimson Wine and Global Self Storage

    Zacks equity research analysts featured five stocks in their daily blog on September 18, 2026. Applied Materials benefits from AI-driven semiconductor demand with an Outperform rating. Philip Morris shows strong pricing power and smoke-free product growth despite declining cigarette volumes. Valero Energy outperforms its industry with favorable refining dynamics. Crimson Wine faces headwinds from weak direct-to-consumer demand and distributor bankruptcy risks. Global Self Storage maintains focus on secondary markets but faces operating cost pressures.

  3. Globenewswire IncResearchandmarkets.Com

    Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

    The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.